

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: ) Examiner: TBA  
 )  
 ICHIKAWA, Yoshitaka, et al. ) Group Art Unit: 1614  
 )  
 Serial No.: 10/580,512 ) Docket No.: 8031-013-US  
 )  
 Filed: May 23, 2006 )  
 )  
 For: Treatment of a Condition)  
 in a Mammal with )  
 Administration of Compounds )  
 and Methods of Use )

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

[submitted via EFS-Web]

Dear Commissioner:

This document is an Information Disclosure Statement to the above-cited patent application and filed pursuant to 37 C.F.R. § 1.97(b) (3). Therefore, no fee is believed to be due.

Attached are forms PTO/SB/08A and PTO/SB/08B listing documents believed relevant to the subject application. The submission of these documents are not intended, nor should they be construed, to constitute an admission that any patent, patent application, article, or other information referred to herein is "prior art" unless specifically designated as such. In fact, applicants submit that these documents do not affect the patentability of the subject invention. In accordance with 37 C.F.R. § 1.97(g), the filing of this information shall not be construed to represent that a search has been made or that no

other material information may exist. Neither should its submission be construed to indicate that a thorough search should not be conducted by the Examiner.

It is respectfully requested that the listing of documents in the attached forms be: (1) fully considered by the Patent and Trademark Office during the prosecution of this application; and (2) represented on any patent which may issue on the application. Applicant respectfully requests that copies of the forms PTO/SB/08A/B, as considered and initialed by the Examiner, be returned with the next communication pursuant to the §609 of the Manual of Patent Examining Procedures (MPEP).

The order of the documents listed in the attached forms is to be accorded no particular import, as the order thereof is completely fortuitous. Additionally, the documents are not necessarily analogous art. A copy of each article document listed in the attached forms is enclosed.

It is believed that this disclosure complies with the requirements as set forth under 37 C.F.R. § 1.56, § 1.97, and § 1.98 and §707.05(b) of the MPEP. If for some reason the Examiner considers otherwise, it is respectfully requested that the undersigned be telephoned at (858) 200-0586 so that any deficiencies can be remedied.

It is further believed that this Information Disclosure Statement is being submitted before the mailing of an Office Action on the merits. Accordingly, no fee is believed to be due under 37 C.F.R. § 197(b)(3). If an Office Action on the merits has in fact been mailed, authorization is hereby given to charge

the required fee of \$180.00 under 37 C.F.R. § 1.97(c)(2) and  
1.17(p) to Deposit Account No. 502235.

Respectfully submitted,



---

David M. Kohn, Esq.  
Reg. No. 53,150  
(858) 200-0588

Date: 7/23/07  
  
CATALYST LAW GROUP, APC  
9710 Scranton Road, Suite 170  
San Diego, California 92121  
(858) 450-0099  
(858) 450-9834 (Fax)